Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

39 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary.
Whitehouse PJ, Winblad B, Shostak D, Bhattacharjya A, Brod M, Brodaty H, Dor A, Feldman H, Forette F, Gauthier S, Hay J, Henke C, Hill S, Mastey V, Neumann P, O'Brien B, Pugner K, Sano M, Sawada T, Stone R, Wimo A. Whitehouse PJ, et al. Among authors: mastey v. Alzheimer Dis Assoc Disord. 1998 Dec;12(4):266-80. doi: 10.1097/00002093-199812000-00006. Alzheimer Dis Assoc Disord. 1998. PMID: 9876955 Clinical Trial.
An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial.
Wimo A, Winblad B, Engedal K, Soininen H, Verhey F, Waldemar G, Wetterholm AL, Mastey V, Haglund A, Zhang R, Miceli R, Chin W, Subbiah P; Donepezil Nordic Study Group. Wimo A, et al. Among authors: mastey v. Dement Geriatr Cogn Disord. 2003;15(1):44-54. doi: 10.1159/000066669. Dement Geriatr Cogn Disord. 2003. PMID: 12457078 Clinical Trial.
Economic evaluation of donepezil in moderate to severe Alzheimer disease.
Feldman H, Gauthier S, Hecker J, Vellas B, Hux M, Xu Y, Schwam EM, Shah S, Mastey V; Donepezil MSAD Study Investigators Group. Feldman H, et al. Among authors: mastey v. Neurology. 2004 Aug 24;63(4):644-50. doi: 10.1212/01.wnl.0000134663.79663.6e. Neurology. 2004. PMID: 15326236 Clinical Trial.
Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD).
Simpson EL, Gadkari A, Worm M, Soong W, Blauvelt A, Eckert L, Wu R, Ardeleanu M, Graham NMH, Pirozzi G, Sutherland ER, Mastey V. Simpson EL, et al. Among authors: mastey v. J Am Acad Dermatol. 2016 Sep;75(3):506-515. doi: 10.1016/j.jaad.2016.04.054. Epub 2016 Jun 4. J Am Acad Dermatol. 2016. PMID: 27268421 Clinical Trial.
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial.
Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, Pariser D, Simpson EL, Papp KA, Hong HC, Rubel D, Foley P, Prens E, Griffiths CEM, Etoh T, Pinto PH, Pujol RM, Szepietowski JC, Ettler K, Kemény L, Zhu X, Akinlade B, Hultsch T, Mastey V, Gadkari A, Eckert L, Amin N, Graham NMH, Pirozzi G, Stahl N, Yancopoulos GD, Shumel B. Blauvelt A, et al. Among authors: mastey v. Lancet. 2017 Jun 10;389(10086):2287-2303. doi: 10.1016/S0140-6736(17)31191-1. Epub 2017 May 4. Lancet. 2017. PMID: 28478972 Clinical Trial.
39 results